Kornimate/medical-research-clean huggingface dataset:
computer-facilitated 5a's for smoking cessation in primary care

Conditions: Nicotine Addiction; Smoking Cessation

Summary: this study tests the use of handheld computer tablets to promote the integration of 5a's (ask, advise, assess, assist, arrange) for smoking cessation in academic and community primary care clinics. although most patients receive the "ask" and "advise" steps, only slightly more than half are "assessed" for readiness to change, less than half receive "assistance" in changing, and only 9% have an "arranged" follow-up. while the large majority of primary care providers support the 5a's model, negative attitudes and the lack of time, knowledge, and cessation skills are common obstacles. alternate service delivery systems that address these obstacles and evidence-based strategies to promote their implementation are needed to improve provider adherence and 5a's fidelity.

this project develops and tests a computer-facilitated 5a's (cf-5a's) model that administers the 5a's intervention to patients then prompts providers for reinforcing next steps. cf-5a's could efficiently and effectively promote smoking cessation while educating providers about cessation resources and appropriate follow-up. based on the technology acceptance model, clinically tailored strategies to promote cf-5a's implementation will be developed and tested to ensure the appropriate use and uptake of this new service delivery model. development of the model, materials, and strategies will occur in years 1 and 2. baseline data collection occurs in year 2, followed by a randomized trial of cf- 5a's where the provider is the unit of randomization. provider use of the 5a's will primarily be assessed with a brief phone call to the patient after the primary care visit has occurred. although focused on 5a's for smoking cessation, this study examines the underlying implementation science of computer-aided service delivery models with important implications for the integration of other substance use or behavioral health interventions in primary care. implementation factors will be assessed using qualitative interviews and brief pre-post surveys.

Eligibility criteria:
inclusion criteria: all primary care providers and clinic staff are eligible to participate. patients must have * a primary care appointment * smoked a cigarette in past 7 days * smoked at least 100 cigarettes in lifetime * speak english or spanish * be cognitively able to use computer tablet exclusion criteria: * moderate to severe cognitive impairment * does not speak english or spanish * acute intoxication on alcohol or illicit drugs

Keywords: smoking 5a's for smoking cessation tailored health messages patient-facing information technology mobile health behavioral health
chest radiography in covid-19 patients

Conditions: Covid19

Summary: to assess the prognostic performance of the rale score with respect to duration of ventilation, and to describe changes in the rale score over time.


Eligibility criteria:
inclusion criteria: * admitted to an icu participating in this study between december 1, 2019 and may 31, 2020 * having had received invasive ventilation * having had received at least one chest radiograph under invasive ventilation * confirmed novel coronavirus diseases (covid-19) exclusion criteria: - age \< 18 years

Keywords: chest radiography ralescore radiographic assessment of lung edema icu invasively ventilated
pantoprazole magnesium 40 mg versus esomeprazole 40 mg in patients with erosive gastroesophageal reflux disease

Conditions: GERD

Summary: the aim of this trial is to evaluate the complete remission of erosive gastroesophageal reflux disease with pantoprazole magnesium 40 mg once daily versus esomeprazole 40 mg once daily during four-week treatment with an extension treatment for non-responding patients. the study includes a baseline period up to 14 days and a treatment period of either 4 weeks (28 -2 + 5 days), or 8 weeks depending on the cure of esophagitis due to gastroesophageal reflux. the study will provide further data on safety and tolerability of pantoprazole magnesium.


Eligibility criteria:
inclusion criteria: * voluntary participation in the study with signature on informed consent form (icf) prior to specific protocol procedures * patients of any race * on outpatient treatment * history of frequent symptom crises related to gerd within the last 3 months (at least a frequency of twice a week, for about four to eight weeks) * diagnosis of erosive esophagitis (grade a to d, according to los angeles classification) * in good health condition, except gerd symptoms * able to follow the protocol directions and to complete daily the questionnaire request™ throughout the study exclusion criteria: * gastrointestinal disorder, even when related to chlorhydropeptic disorders: barret's esophagus, peptic ulcer, zollinger-ellison syndrome and pyloric stenosis * previous history of surgery to reduce acid secretion, or other upper gastrointestinal tract surgeries (excepting polypectomy and cholecystectomy) * at initial endoscopy presenting complicated disorders due to erosive esophagitis: obstructive esophageal stenoses, schatzki ring, esophageal diverticulum, esophageal varices, achalasia and hiatal hernia * pregnant women or during nursing period * proton pump inhibitors (ppis) within the last 10 days prior to start of the study * triple therapy based on ppis to eradicate h. pylori within the last 28 days prior to start of the study * h2-blockers, sucralfate and prokinetics within the last 7 days prior to start of the study * systemic glucocorticoids and/or nonsteroidal anti-inflammatory drugs (including cox-2 inhibitors) for more than 3 consecutive days a week, within the last 28 days prior to start of study, with exception of regular intake of acetyl salicylic acid in dosages of up to 163 mg/day.

Keywords: gastroesophageal pantoprazole erosive erosive gerd grades a-d, acc. to los angeles classification
first-in-human single ascending dose of shr0302

Conditions: Rheumatoid Arthritis

Summary: the purpose of the study is to evaluate the safety and tolerability of single ascending (sad) oral doses of shr0302 compared to placebo. also, pharmacokinetics (pk) and pharmacodynamics (pd) of shr0302 after single oral administration will be evaluated, and, if applicable, the maximum tolerated dose determined.


Eligibility criteria:
inclusion criteria: * healthy subjects, age 18-45 years (inclusive); * the weight of the subject should be more than 50 kg, body mass index (bmi = weight/height squared (kg/m2)) within the range of 19 to 24. exclusion criteria: * any condition that might interfere with the procedures or tests in the study * history of heart failure or renal insufficiency * smoking; drug or alcohol abuse
car t cells for refractory b cell malignancy

Conditions: B-Cell Leukemia; B-Cell Lymphoma

Summary: chimeric antigen receptor (car) t cells targeting cd19 will be evaluated for safety and efficacy in patients with b cell malignancy including lymphoma or leukemia.

the car consists of a cd19 targeting antibody scfv with three intracellular signaling domains derived from cd3 zeta, cd28 and 4-1bb. autologous t cells will be gene engineered with the car gene using a lentivirus vector. prior to t cell infusion, the patients will be subjected to preconditioning treatment. after t cell infusion, the patients will be evaluated for 24 months for adverse reactions, persistence of car t cells and efficacy.

Eligibility criteria:
inclusion criteria: 1. the treat history meeting the following criteria: * recurrence of lymphoma patients with imaging (ct/mri/pet-ct) detection and pathological diagnosis, or recurrence including bone marrow morphology relapse and the mrd recurrence of myeloma patients or leukemia patients, after chemotherapy or stem cell transplantation; * can't get complete remission (including mrd positive) after more than twice repeated chemotherapy of incipient lymphoma, myeloma or leukemia patients; * one or twice chemotherapy cannot get remission again (including mrd positive), but not suitable for chemotherapy of incipient lymphoma, myeloma or leukemia patients. 2. there is a measurable lesions before treatment at least; 3. ecog score≤2; 4. to be aged 1 to 70 years; 5. more than a month lifetime from the consent signing date exclusion criteria: * serious cardiac insufficiency, left ventricular ejection fraction\<50; * has a history of severe pulmonary function damaging; * merging other malignant tumor; * merging uncontrolled infection; * merging the metabolic diseases (except diabetes); * merging severe autoimmune diseases or immunodeficiency disease; * patients with active hepatitis b or hepatitis c; * patients with hiv infection; * has a history of serious allergies on biological products (including antibiotics); * happened in 3 \~ 4 acute gvhd after allogeneic hematopoietic stem cell transplantation on recurring patients pregnancy or lactation women; any situation that would increase dangerousness of subjects or disturb the outcome of the clinical study according to the researcher's evaluation.
pattern of use of bevacizumab or cetuximab + folfiri regimen as first-line treatment in metastatic colorectal cancer

Conditions: Metastatic Colorectal Cancer

Summary: * registry * multicenter, prospective observational study * observe adverse events and efficacy in recruited patients for 3 years under real world settings.


Eligibility criteria:
inclusion criteria: 1. adult patients at least 19 years of age with metastatic colorectal cancer who are planned to receive bevacizumab or cetuximab in combination with folfiri regimen as first-line treatment 2. patients who will receive irinotecan, a component of folfiri regimen, using camtop injection® exclusion criteria: 1) patients with conditions in which any study drug is contraindicated per the respective approved label.
deep friction massage: symptomatic

Conditions: Tendinopathy

Summary: despite dfm being a widely-used technique and the empirical grounding regarding the importance of the pressure applied, there is no study characterizing the pressure applied during dfm, remaining it a discretion of the physiotherapist. additionally, it is not known how the amount of pressure applied may influence pain mechanisms or function in the symptomatic patellar tendon. having this, our objective is to characterize the pressure applied during deep friction massage and evaluate the immediate effects of different pressures applied during deep friction massage in the time until analgesia as well as in function, in patellar tendinopathy.


Eligibility criteria:
inclusion criteria: * the participants should have a symptomatic patellar tendon exclusion criteria: * history of other previous injuries of the lower limbs; * intake of medication that could interfere with pain mechanisms; * presence of any factors or conditions that could interfere with the awareness and sensibility to pain.

Keywords: patellar tendon
pharmacogenetic factors and side effects of metoclopramide and diphenhydramine

Conditions: Drug Metabolism, Poor, CYP2D6-RELATED

Summary: pharmacokinetic of metoclopramide (mcp) in correlation to polymorphisms of cyp2d6 and dopamine-d2-receptor. pharmacokinetic of diphenhydramine (dph) in correlation to polymorphisms of cyp2d6


Eligibility criteria:
inclusion criteria: * bmi 20 - 27kg/m2 * caucasians * healthy volunteers exclusion criteria: * pregnancy/lactation period * drug allergy * acute and chronic diseases * taking medication * abuse of drugs, alcohol etc. * smoker

Keywords: pharmacokinetic pharmacogenetic metoclopramide diphenhydramine cyp2d6 polymorphisms
resident memory t cells in vitiligo

Conditions: Vitiligo

Summary: this study aims to detect the presence and diversity of tissue resident memory t cell populations in early and late cases of generalized non-segmental vitiligo.

* written informed consent obtained from every participant. * detailed history taking including onset, course, duration of the disease, aggravating factors and received medications * vasi score assessed in every patient. * patients photographed, divided into two groups early \& late cases and 3 mm punch biopsies will be taken from perilesional and non lesional skin. * biopsies processed and stained for cd8 \& cd69 in cases of early group, \& late group and controls by immunofluorescence.

Eligibility criteria:
inclusion criteria: * - patients with generalized non-segmental vitiligo ( lesions in more than one anatomical site ). * both genders. * early group: onset less than or equal 6 months. * late group: onset more than 6 months exclusion criteria: * localized or segmental vitiligo. * age \< 14 years. * pregnant females * patient who received treatment of any type within the last 3 months for the late group. * patients with other skin diseases or immunosuppression
clinical study to evaluate the maximum tolerated dose of bay1000394 when given together with chemotherapy and the effectiveness of this combination treatment in shrinking a specific type of lung tumors (small cell lung cancer)

Conditions: Small Cell Lung Carcinoma

Summary: this is the first study where bay1000394 is given in combination with chemotherapy: cisplatin / etoposide or carboplatin / etoposide. patients with small cell lung cancer will be treated. every patient will receive drug treatment, there is no placebo group. different groups of patients will receive different dosages of bay1000394 to determine the safety and maximum tolerated dose (mtd) of bay1000394 in combination with chemotherapy. the dose of chemotherapy is the standard dose usually administered and will not change. the study will also assess how the drug is metabolized by the body and changes in tumor size. bay1000394 will be given per mouth, twice a day for three days every week. treatment will stop if the tumor continues to grow, if side effects occur which the patient can not tolerate or if the patients decides to exit treatment.


Eligibility criteria:
inclusion criteria: * male or female subjects aged \>/=18 years * histologically or cytologically confirmed, extensive disease sclc * at least 1 solid tumor lesion measurable by computer tomography (ct) scan or magnetic resonance imaging (mri) according to recist 1.1. subjects with non-measurable disease according to recist 1.1 can be included in the phase ib part of the study * eastern cooperative oncology group (ecog) performance status of 0 - 1 * life expectancy of at least 12 weeks * serum sodium \>/=130 mmol/l exclusion criteria: * prior systemic anticancer therapy * prior radiotherapy (local palliative radiotherapy is permitted) * history of cardiac disease: congestive heart failure \> nyha class ii, unstable angina (anginal symptoms at rest), any episodes of angina or history of myocardial infarction, cardiac arrhythmias requiring anti-arrhythmic therapy (beta blockers or digoxin are permitted), previous venous or arterial thrombotic events, pulmonary embolism * moderate or severe hepatic impairment, ie child-pugh class b or c * known human immunodeficiency virus (hiv) infection or chronic hepatitis b or c

Keywords: cyclin dependent kinases drug therapy, combination small cell lung carcinoma etoposide cisplatin carboplatin
real world evidence of the effectiveness of paritaprevir/r - ombitasvir, ± dasabuvir, ± ribavirin and patient support program in patients with chronic hepatitis c

Conditions: Chronic Hepatitis C

Summary: the interferon-free combination regimen of ombitasvir/paritaprevir/ritonavir/ with or without dasabuvir (abbvie regimen) ± ribavirin (rbv) for the treatment of chronic hepatitis c (chc) has been shown to be safe and effective in randomized controlled clinical trials with strict inclusion and exclusion criteria under well controlled conditions. this observational study was the first effectiveness research examining the abbvie regimen ± rbv, used according to local label, under real world conditions in israel in a clinical practice patient population.

this was a prospective, multi-center observational study in participants receiving the interferon-free abbvie regimen ± rbv in israel. the prescription of a treatment regimen was at the discretion of the physician in accordance with local clinical practice and label, was made independently from this observational study and preceded the decision to offer the participant the opportunity to participate in this study. adults chronically infected with hcv, receiving the interferon-free abbvie regimen, were offered the opportunity to participate in this study during a routine clinical visit at the participating sites. follow-up visits, treatment, procedures, and diagnostic methods followed physicians' routine clinical practice. data were collected at the following time windows: baseline, early on-treatment visit, mid-treatment visit (for participants with a treatment duration of 24 weeks), end of treatment (eot), early post-treatment and 12 and 24 weeks after the end of treatment (representing sustained virologic response 12 weeks after the end of treatment \[svr12\] and sustained virologic response 24 weeks after the end of treatment \[svr24\]).

Eligibility criteria:
* treatment-naïve or -experienced adult male or female participants with confirmed chronic hepatitis c (chc), genotype 1 or 4, receiving combination therapy with the interferon-free abbvie regimen ± ribavirin (rbv) according to standard of care and in line with the current local label * if rbv was co-administered with the abbvie regimen, it had to be prescribed in line with the current local label (with special attention to contraception requirements and contraindication during pregnancy) * participants had to voluntarily sign and date an informed consent form prior to inclusion into the study * participants must not have participated or intended to participate in a concurrent interventional therapeutic trial exclusion criteria: - none

Keywords: chronic hepatitis c ombitasvir/paritaprevir/ritonavir ± dasabuvir sustained virological response observational study chronic hepatitis c genotype 1 chronic hepatitis c genotype 4
national register studies in thoracic surgery

Conditions: Lung Cancer; Pulmonary Metastasis; Surgery

Summary: the overall project aim is to study risk and outcomes following thoracic surgery by cross-linking high-quality national swedish health-data registers for population-based investigations of individual level clinically relevant patient data.

the purpose of this research project is to study risks and outcomes in patients who underwent thoracic surgery, primarily for lung cancer. we aim to establish a fundament for the conduct of nationwide population-based studies by linking patient-level data from the swedish quality register for thoracic surgery (thor) and other national health-data registers maintained by the government agencies statistics sweden and the national board of health and welfare. cross-linking patient-level data is possible through the personal identity number assigned to every individual who has resided in sweden on a permanent basis. the swedish personal identity number is the unique identifier in all national registers. specifically, we aim: 1. to analyze the association between socioeconomic factors and prognosis in patients undergoing pulmonary resection for lung cancer. 2. to investigate the implementation of minimally invasive surgery for lung cancer in sweden.

Eligibility criteria:
inclusion criteria: all adult patients who underwent thoracic surgery in sweden during the study period exclusion criteria: -

Keywords: thoracic surgery lung surgery epidemiologic methods
study to evaluate the efficacy and safety of jte-451 in subjects with moderate to severe plaque psoriasis

Conditions: Plaque Psoriasis; Psoriasis; Skin Diseases

Summary: study to evaluate the efficacy and safety of jte-451 administered for 16 weeks in subjects with moderate to severe plaque psoriasis.


Eligibility criteria:
inclusion criteria: * have had a history of moderate to severe plaque psoriasis for at least 6 months prior to visit 1; * subjects with moderate to severe plaque psoriasis covering ≥10% body surface area (bsa), with a psoriasis area and severity index (pasi) ≥12 and static physician's global assessment (spga) score ≥3 at visit 1 and visit 2 exclusion criteria: * history of discontinuation of biologic therapies (including marketed and investigational drugs) directly targeting interleukin (il)-17a, il-17a/f, il-17 receptor a, il-12/il-23p40 or il-23p19 due to lack of efficacy, according to the investigator's judgment; * prior exposure to retinoid-related orphan receptor (ror)-γ inhibitors; * presence of erythrodermic psoriasis, pustular psoriasis, guttate psoriasis, medication-induced psoriasis or other skin conditions (e.g., clinically-significant eczema or severe acne) at visit 1; * history or presence of itch due to underlying conditions other than plaque psoriasis which cause or influence pruritus of the skin within 12 months prior to visit 1.

Keywords: jte-451 psoriasis plaque psoriasis impact-ps
iort in local advanced laryngocarcinoma

Conditions: Laryngeal Neoplasms

Summary: the incidence of laryngeal cancer accounts for about 1 \~ 5% of the total body tumors. for the surgical treatment of laryngeal cancer, the development trend of laryngocarcinoma treatment is to improve the local control rate, preserve the laryngeal function of patients as far as possible, and improve the life quality of patients. the efficacy, safety and feasibility of intraoperative radiotherapy (iort) in head and neck cancer has been demonstrated in multiple institutional (3-5) studies to optimize local control. it is still unclear whether iort can improve the local control and have efficacy, safety and feasibility in clinic. the purpose of this study was to observe the efficacy, safety and feasibility of iort in local advanced laryngocarcinoma .


Eligibility criteria:
inclusion criteria: 1. adults over the age of 18; 2. radiographic or pathological diagnosis of local advanced laryngocarcinoma (according to nccn guidelines); 3. the expected survival time ≥ 3 months; 4. sign informed consent for treatment and research with self-knowledge. exclusion criteria: 1. there is distant metastasis; 2. pregnant women; 3. patients with ct/mri contraindications; 4. the patient fails to receive treatment and/or follow-up as scheduled; 5. bad fluid and organ function decompensation; 6. multiple primary cancers; 7. patients participating in other trials.